Abstract
Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Current Topics in Medicinal Chemistry
Title: Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act
Volume: 10 Issue: 18
Author(s): Susanne H. Goodson
Affiliation:
Keywords: Research tools, Merck, AbTox, Eli Lilly, Proveris, Safe Harbor Provision, Hatch-Waxman Act, Federal law, Investigational New Drug Applica-tion, New Drug Ap-plication, Patent Term Restoration Act, Abbreviated New Drug, flurazepam, Federal Food, Drug, and Cosmetic Act, hybridoma tech-nology, FDCA, PHS Act, Federal Circui, FDA regulation, Arg-Gly-Asp, RGD, Merck's preclinical experimentation, ANDA, EMD 121974, v3 receptors, angio-matrigel test, FDA's guidelines, U.S. Patent No. 4,879,237, U.S. Patent No. 4,789,734, IC50 or EC50
Abstract: Many facets of drug discovery involve the use of patented materials and methods, subjecting the researcher to potential liability from infringement of the underlying patents. Enacted in 1984, the Hatch-Waxman Act established a “safe harbor” for activities that would otherwise constitute infringement of a patented invention, if those activities were “solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products”. This article examines the major court decisions interpreting the scope of the safe harbor and their application to various activities in drug development.
Export Options
About this article
Cite this article as:
H. Goodson Susanne, Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act, Current Topics in Medicinal Chemistry 2010; 10 (18) . https://dx.doi.org/10.2174/156802610793176693
DOI https://dx.doi.org/10.2174/156802610793176693 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Current Pharmaceutical Design Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Biological Interfacial Engineering for Metastatic Cancer Diagnosis and Intervention
Current Medicinal Chemistry Gene Electrotransfer in 3D Reconstructed Human Dermal Tissue
Current Gene Therapy Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
Current Molecular Pharmacology A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
Current Cancer Drug Targets Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry